Phaidros Healthcare and Berlin-based medtech company Epinamics GmbH, have signed a letter of intent for the commercialization of pharmaceutical products based on Epinamic’s proprietary Liqui-Patch® technology.
The polymer based, sprayable and film forming drug delivery technology, which allows for the addition of active ingredient onto the spray, offers unique benefits vs. oral dosing or transdermal patches and gels.
Current development projects span across a number of clinical applications in CNS (Alzheimer’s and Parkinson’s Disease), Hormone Replacement Therapy and Dermatology.
The companies expect to benefit from Epinamics’s strong R&D capabilities and Phaidros’s commercial reach in the Asia-Pacific region.
Phaidros is a young healthcare company focusing on the development and commercialization of strongly differentiated non-prescription drugs and medical devices, especially in the therapeutic areas reproductive medicine and intimate care. Phaidros also offers market access and expansion services for the Asia-Pacific region.
The company has offices in Singapore and Berlin.
Epinamics is a Berlin-based, privately owned research and development company, focusing on a patent protected drug delivery technology for dermal and transdermal applications of pharmaceutical and cosmeceutical products.